Ivermectin, a drug normally used to treat parasites including lice and rabies, did not seem to have a significant impact and improve the symptoms of patients with Covid-19, according to new research published Thursday, in the Journal of the American Medical Association.
In January, the National Institutes of Health’s Treatment Guidelines Panel said that there is not enough data to recommend for or against the drug to treat Covid-19 patients.
Even without studies to demonstrate that it works, a few doctors have heavily promoted the drug. It’s a cheap medication with anti-inflammatory properties and it seemed to stop the virus from replicating in lab studies. But just because it works in the lab, doesn’t mean it will work in real life. Most mainstream physicians have reserved their judgment about it
In this study based in Cali, Colombia, nearly 500 adults with mild disease who had symptoms for 7 days, volunteered to help test the drug. The trial is what’s known as a double-blind randomized control trial, the gold-standard of trials.
Half the volunteers got the drug for five days, the other half got a placebo, and standard care. Patients were enrolled in the trial between July 2020 and November 2020 and doctors followed up with that through December.
At the end of the trial, there were a nearly equal number of adverse events (mostly headache) in both groups of volunteers. The patients who got the drug said their symptoms subsided by 10 days. For the group that got the placebo, it was 12 days. Two days was not considered a “significant” improvement.
“The findings do not support the use of ivermectin for treatment of mild COVID-19,” the study concludes. It adds that larger trials may be needed to better understand if ivermectin provides any other kind of benefit to patients with Covid-19. In this case, the study focused on symptoms and mild disease.